MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/105/0.1/20.12.24 Share Price

Warrant

DE000MB331L0

Real-time Bid/Ask 07:16:07 02/07/2024 pm IST
0.046 EUR / 0.049 EUR -2.04% Intraday chart for MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/105/0.1/20.12.24
Current month-3.92%
1 month+104.17%
Date Price Change
02/24/02 0.045 -8.16%
01/24/01 0.049 -3.92%
28/24/28 0.051 +8.51%
27/24/27 0.047 -2.08%
26/24/26 0.048 -4.00%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 05:29 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying GILEAD SCIENCES, INC.
Issuer Morgan Stanley
WKN MB331L
ISINDE000MB331L0
Date issued 01/02/2023
Strike 105 $
Maturity 20/12/2024 (171 Days)
Parity 10 : 1
Emission price 0.59
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.7
Lowest since issue 0.014
Spread 0.003
Spread %6.00%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
More about the company

Ratings for Gilead Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Gilead Sciences, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.64 USD
Average target price
82.97 USD
Spread / Average Target
+20.87%
Consensus